SSR2 Promotes Sorafenib Resistance Via Interacting with GPX4 to Inhibit Ferroptosis.

Zebing Song; Mengdan Zhou; Xiaodong Song; Hongyun Jia; Xia Yang

doi:10.2174/0115665240405981251201125139

January 9, 2026

SSR2 Promotes Sorafenib Resistance Via Interacting with GPX4 to Inhibit Ferroptosis.

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to uncover how SSR2 contributes to sorafenib resistance in hepatocellular carcinoma (HCC) by interacting with GPX4 to inhibit ferroptosis.
Investigated the interaction between SSR2 and GPX4.
Analyzed the impact of SSR2 on ferroptosis in HCC cells.
Assessed sorafenib resistance levels in response to SSR2 expression.
SSR2 was found to enhance resistance to sorafenib in HCC.
The interaction between SSR2 and GPX4 was confirmed.
Inhibition of ferroptosis was linked to increased SSR2 levels.

Implication

Basic research reveals SSR2's role in sorafenib resistance in HCC, suggesting new treatment targets.

Abstract

In summary, we reveal that SSR2 enhances sorafenib resistance of HCC via interacting with GPX4 and inhibiting ferroptosis, providing a potential target for HCC treatment. The molecular mechanism of GPX4-SSR2 interaction in ferroptosis will be further studied.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Song et al. (2026) studied this question.

synapsesocial.com/papers/6974616cbb9d90c67120b377 https://doi.org/10.2174/0115665240405981251201125139

View Full Paper

Ask AI

Bookmark

Share

SSR2 Promotes Sorafenib Resistance Via Interacting with GPX4 to Inhibit Ferroptosis.

Key Points

Implication

Abstract

Discussion

Cite This Study

SSR2 Promotes Sorafenib Resistance Via Interacting with GPX4 to Inhibit Ferroptosis.

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading